Hyaluronan conjugates and uses thereof
Inventors
LEE, Szu-Yuan • LAI, Ping-Shan • Lin, Chih-An
Assignees
National Chung Hsing University • Holy Stone Healthcare Co Ltd • Aihol Corp
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12128108-B2
Publication Date
2024-10-29
Expiration Date
Abstract
Disclosed herein is a method of using a hyaluronan conjugate, which includes a hyaluronic acid (HA), a sex hormone, and a linker for coupling one of the disaccharide units of the HA and the sex hormone. The hyaluronan conjugates are used in treating neurodegenerative diseases.
Core Innovation
The invention concerns hyaluronan (HA; hyaluronic acid)–sex hormone conjugates for treating neurodegenerative diseases in a subject in need thereof by administering an effective amount. The conjugate comprises HA or a salt thereof covalently coupled to a sex hormone selected from estrone, estradiol, estriol, testosterone, and 11-deoxycorticosterone via a linker selected from one or more amino acids, lipid, dihydrazide-C2-C20 dicarboxylic acid, and C2-C20 dicarboxylic acids.
The sex hormone is covalently coupled with one of the disaccharide units of the HA or a salt thereof. The conjugates are characterized by a sex-hormone degree of substitution of 0.1% to 60% and a HA weight-average molecular weight of about 5 to 500 kDa.
The HA conjugate improves cognitive function and/or sensorimotor function of the subject, and is used in a method of treating neurodegenerative diseases involving loss of cognitive function and/or sensorimotor function. The invention further specifies that the neurodegenerative disease includes Alzheimer’s disease.
Claims Coverage
The independent claims are directed to treating neurodegenerative disease by administering an effective amount of a hyaluronan conjugate, with four inventive features.
Covalently coupled sex hormone–HA hyaluronan conjugate via disaccharide unit
A hyaluronic acid (HA) or a salt thereof, a sex hormone selected from estrone, estradiol, estriol, testosterone, and 11-deoxycorticosterone, and a linker covalently coupling the sex hormone with one of the disaccharide units of the HA or a salt thereof.
Linker selected from amino acids, lipid, dihydrazide-C2–C20 dicarboxylic acid, and C2–C20 dicarboxylic acids
The linker is selected from one or more amino acids, lipid, dihydrazide-C2–C20 dicarboxylic acid, and C2–C20 dicarboxylic acids.
Improves cognitive function and/or sensorimotor function in treating neurodegenerative disease
The HA conjugate improves the cognitive function and/or sensorimotor function of the subject, and the neurodegenerative disease involves loss of cognitive function and/or sensorimotor function.
Alzheimer’s disease treatment using the sex hormone–HA conjugate
The neurodegenerative disease is Alzheimer's disease.
The claim coverage centers on treating neurodegenerative disease with a sex hormone–HA conjugate linked through a specified linker, with therapeutic effect stated as improvement of cognitive function and/or sensorimotor function; one claim specifically requires Alzheimer’s disease.
Stated Advantages
Improved therapeutic effects while reducing unwanted sex-hormone side effects on other organs.
The HA conjugate improves the cognitive function and/or sensorimotor function of the subject.
Documented Applications
Treatment of neurodegenerative diseases in a subject in need thereof by administering an effective amount of a hyaluronan–sex hormone conjugate, including Alzheimer's disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington’s disease, frontotemporal dementia, epilepsy, neuropathic pain, and ataxia.
Interested in licensing this patent?